Faeth Therapeutics, Inc.

Founded in 2019 and based in California, US, Faeth Therapeutics, Inc. , d. b. a.

Faeth, operates as a clinical-stage biotechnology company that develops nutrition solutions for battling cancer among patients. In October 2025, Faeth Therapeutics, Inc. secured USD 25 million in Series A funding, led by S2G Investments, with participation from B Group Capital, Avicella, and THO Seed Fund. Faeth operates a learning-driven preclinical discovery platform called MetabOS which identifies the impact of tumors based on genotype, organ of origin, and therapy.

Patients are onboarded into a highly personalized precision nutrition program combining meals, therapeutics, and advice from a tea of dieticians. The meals are delivered to the patient's door. The company's team consists of high-profile scientists including Lew Cantley, director of the Meyer Cancer Center at Weill Cornell Medicine and Sid Mukherjee, an oncologist at Columbia University Irving Medical Center. Faeth Therapeutics generates revenue through clinical-stage oncology programs, precision nutrition services, and its MetabOS platform, combining drug therapies with metabolic optimization for cancer treatment.

The company will use the October 2025 funding to advance its endometrial cancer program, expand its MetabOS platform, support a rectal cancer study, and prepare for a clinical entry in a rare pediatric disorder.